Zentalis Pharmaceuticals (ZNTL) Assets Average (2020 - 2026)

Zentalis Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $271.0 million for Q1 2026.

• In Q1 2026, Assets Average fell 33.44% year-over-year to $271.0 million; the TTM figure through Mar 2026 stood at $271.0 million (down 33.44% YoY), while the FY2025 annual figure was $359.7 million, down 26.75% from the prior year.
• Assets Average was $271.0 million for Q1 2026 at Zentalis Pharmaceuticals, down from $308.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $603.6 million in Q3 2023 to a low of $271.0 million in Q1 2026.
• Historically, Assets Average has averaged $466.2 million across 5 years, with a median of $486.8 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Assets Average surged 58.99% in 2022, then tumbled 33.44% in 2026.
• A 5-year view of Assets Average shows it stood at $534.3 million in 2022, then advanced by 6.45% to $568.7 million in 2023, then slipped by 22.54% to $440.5 million in 2024, then slumped by 30.05% to $308.1 million in 2025, then declined by 12.04% to $271.0 million in 2026.
• The last three Assets Average figures came in at $271.0 million (Q1 2026), $308.1 million (Q4 2025), and $339.5 million (Q3 2025), per Business Quant data.